Although there are treatments currently available with a proven track record against rare types of cancers, such as Waldenstrom macroglobulinemia, with any treatment, however successful, there will be a handful of (or more) patients that do not respond to it. For these individuals, alternative forms of treatment are needed.
There’s good news for these resistant patients, and we’re here to share it with you!
Sunesis pharmaceuticals recently (July 18, 2017) announced that their first Waldenstrom macroglobulinemia patient has been administered its new developing therapy, SNS-062, in their Phase 1b/2 clinical trial. This clinical trial was aimed to increased the dosage of SNS-062 and increase the number of patients it was being given to.
SNS-062 is a reversible, non-covalent Bruton’s Tyrosine kinase- (BTK)-inhibitor that is intended for adult patients with Waldenstrom macroglobulinemia, small lymphocytic leukemia, chronic lymphocytic leukemia (CLL), and mantle cell lymphoma that have been resistant to previous therapies.
Researchers are hopeful about this new oral inhibitor, as BTK is a validated target in the treatment of B-cell malignancies. SNS-062 has shown success in preclinical studies, and Sunesis is now looking forward to the phase 1b/2 open-label, sequential-group study.
If you want to learn more about this drug from Global Newswire, click here.
Along similar lines, the biopharmaceutical company ArQule, Inc. recently announced that their first patient has been dosed in their phase 1a/b trial with their BTK inhibitor, ARQ 531. Again, this inhibitor aims to target B-cell malignancies in patients when other treatments (notably, Imbruvica) fail them.
If the phase 1a trial is completed properly, the phase 1b trial can proceed to solidify early signs of activity and proof of concept.
To learn more about this BTK-inhibitor, read this page from Business Insider.